Transcutaneous supraorbital neurostimulation for the prevention of chronic migraine: a prospective, open-label preliminary trial
- 563 Downloads
Since chronic migraine is difficult to treat and often associated with medication overuse, non-invasive neurostimulation approaches are worth investigating. Transcutaneous supraorbital neurostimulation using the Cefaly® device is promising as a non-invasive preventive treatment for episodic migraine, but no data are available for chronic migraine. Our aim was to perform a preliminary evaluation of the efficacy of the Cefaly® device for the prophylaxis of chronic migraine with or without medication overuse. Primary endpoints were 50% reduction in monthly migraine days and 50% reduction in monthly medication use over 4 months. In an open-label study, twenty-three consecutive headache center patients with chronic migraine, diagnosed according to International Headache Society criteria, were recruited prospectively. After informed consent, patients were trained to use Cefaly® and instructed to use it for 20 min daily over 4 months. All patients received active neurostimulation. Thirty-five percent of the patients enrolled in the study achieved the study endpoints. Over half the patients had a greater than 50% reduction in acute medication consumption.
KeywordsChronic migraine Migraine prophylaxis Medication overuse Transcutaneous supraorbital neurostimulation
Compliance with ethical standards
This study had no external funding source. Cefaly® devices were made available by the manufacturer (Cefaly Technology, Liège, Belgium) free of charge, for use in the study, Cefaly® Technology had no role in the design or conduct of the study
Conflict of interest
The authors certify that there is no actual or potential conflict of interest in relation to this article.